Skip to main content

Advertisement

Table 2 In vitro cytotoxicity of sorafenib, sunitinib, irinotecan and SN-38 against three AT/RT cell lines

From: Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Inhibitor, IC50 (μM) BT 12 BT 16 KCCF1
Sorafenib 3.3 2.8 3.6
Sunitinib 3.2 3.2 3.7
Irinotecan 2.0 4.1 6.7
SN-38 0.09 0.03 4.6
  1. IC50 - half maximal inhibitory concentration